Development of a diagnostic for latent TB

潜伏性结核病诊断方法的开发

• 批准号: 8535548
• 负责人: FREDERICK D QUINN
• 金额: $ 20万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-17 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8535548
• 关键词: Development; diagnostic; latent; TB

The Institute of Medicine report, "Ending Neglect: The Elimination of Tuberculosis in the United States," calls for the development of better tools for accurately identifying latently infected individuals. In countries such as the United States, where the incidence of latent tuberculosis is relatively low, the specificity of the current tuberculin skin test is too low to yield a high positive power of prediction. The goal of the proposed research is proof of concept for a diagnostic test of very high specificity, based upon the ultra sensitive detection of a Mycobacterium tuberculosis (Mtb) protein in peripheral blood. The specific aims are: to develop a bead capture ELISA sensitive enough to detect the Mtb homolog of alpha-crystallin at a low picomolar concentration, and to demonstrate that this protein can be detected in sera from Mtb - infected subjects. If this very specific and sensitive diagnostic test can be developed and commercialized, it could be used to guide prophylactic treatment recommendations for individuals latently infected with Mtb. Such a test has been identified as a high priority goal to facilitate a National plan to eliminate tuberculosis in the United States.

医学研究所报告：“结束忽视：消除联合的结核病 国家，“呼吁开发更好的工具，以准确识别潜在的感染 个人。在美国等国家，潜在结核病发生率是 相对较低，当前结核蛋白皮肤测试的特异性太低，无法产生高阳性 预测的力量。 拟议的研究的目的是进行非常高的诊断测试的概念证明 特异性，基于对结核分枝杆菌（MTB）的超敏感检测 外周血中的蛋白质。具体目的是：开发珠子捕获ELISA敏感 足以检测低皮摩尔浓度下α-晶状蛋白的MTB同源物，并 证明可以在MTB感染受试者的血清中检测到该蛋白质。 如果可以开发和商业化此非常具体和敏感的诊断测试，则可以 用于指导针对患有潜在感染的个体的预防治疗建议 MTB。这种测试已被确定为促进国家计划的高优先目标 消除美国的结核病。